Van ECK Associates Corp Purchases 929 Shares of Guardant Health, Inc. (NASDAQ:GH)

Van ECK Associates Corp raised its position in Guardant Health, Inc. (NASDAQ:GH) by 47.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,887 shares of the company’s stock after purchasing an additional 929 shares during the quarter. Van ECK Associates Corp’s holdings in Guardant Health were worth $88,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Entropy Technologies LP bought a new position in shares of Guardant Health during the fourth quarter worth about $377,000. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Guardant Health by 19.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,464,213 shares of the company’s stock worth $44,732,000 after acquiring an additional 238,037 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Guardant Health by 10.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,198 shares of the company’s stock worth $800,000 after acquiring an additional 2,537 shares during the last quarter. R Squared Ltd bought a new position in shares of Guardant Health during the fourth quarter worth about $26,000. Finally, KBC Group NV raised its position in shares of Guardant Health by 63.6% during the fourth quarter. KBC Group NV now owns 5,658 shares of the company’s stock worth $173,000 after acquiring an additional 2,200 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Raymond James restated an “outperform” rating and set a $59.00 price objective (up from $39.00) on shares of Guardant Health in a research report on Friday. Sanford C. Bernstein decreased their target price on Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. JPMorgan Chase & Co. raised their target price on Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research note on Friday. Stifel Nicolaus raised their target price on Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a research note on Friday. Finally, The Goldman Sachs Group raised their target price on Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a research note on Friday. Eighteen analysts have rated the stock with a buy rating, Based on data from MarketBeat, Guardant Health presently has an average rating of “Buy” and an average target price of $44.78.

Guardant Health Stock Performance

Shares of Guardant Health stock opened at $42.87 on Monday. The stock has a 50 day moving average price of $40.19 and a two-hundred day moving average price of $31.57. The stock has a market capitalization of $5.30 billion, a PE ratio of -12.04 and a beta of 1.32. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $50.89.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). The business had revenue of $201.81 million for the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. Research analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Insider Buying and Selling

In other Guardant Health news, Director Musa Tariq sold 2,320 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the sale, the director now directly owns 2,676 shares in the company, valued at $93,660. The trade was a 46.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last three months, insiders have sold 2,768 shares of company stock worth $98,798. 5.50% of the stock is owned by company insiders.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.